-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $13

Benzinga·11/18/2026 13:52:45
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.